Analyzing Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)

Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Earnings & Valuation

This table compares Intellia Therapeutics and BeyondSpring”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67 million	23.21	-$412.69 million	($3.36)	-3.34
BeyondSpring	$1.75 million	10.13	-$1.01 million	($0.12)	-3.59

BeyondSpring has lower revenue, but higher earnings than Intellia Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Intellia Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Intellia Therapeutics and BeyondSpring, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	5	8	9	1	2.26
BeyondSpring	1	0	0	0	1.00

Intellia Therapeutics presently has a consensus price target of $20.72, indicating a potential upside of 84.81%. Given Intellia Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than BeyondSpring.

Profitability

This table compares Intellia Therapeutics and BeyondSpring’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
BeyondSpring	N/A	N/A	-28.88%

Insider and Institutional Ownership

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 29.3% of BeyondSpring shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Intellia Therapeutics beats BeyondSpring on 9 of the 15 factors compared between the two stocks.

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.